| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs7849270 | C-glycosyltryptophan* / succinylcarnitine | A/G | 6530 | 0.3 | 0.025 (0.003) | 2.82·10-21 | show |
| rs10988217 | succinylcarnitine | A/G | 6552 | 0.39 | -0.016 (0.002) | 1.36·10-18 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs10988217 |
| Chromosomal location | Chr9: 130,914,462 (9q34.11) |
| Gene (distance) | CRAT (15,047) |
| Predicted causal gene | CRAT |
| Gene/protein classification | - |
| Metabolite (Pathway) | C-glycosyltryptophan* (Tryptophan metabolism; Amino acid) succinylcarnitine (Krebs cycle; Energy) |
| Biochemical locus-metabolite relationship | CRAT encodes carnitine O-acetyltransferase, which catalyzes the interconversion of short chain acylcarnitines and acyl-coenzyme A derivatives. CRAT has maximal activity for propionyl-CoA [2351134]. Ratio interpretation: n/a. |
| eQTL associations | CRAT (L), ENDOG (L), IER5L (L), PPP2R4 (F), PPP2R4 (S) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information | |
|---|---|
| Complex trait associations | - |
| Known metabolite associations | - |
| Inborn error of metabolism | - |
| Pharmacological information | |
|---|---|
| ChEMBL ID | CHEMBL3184 |
| Drug information | Compounds with no inhibitory activity in ChEMBL |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








